Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 27, 2011 Brian Orelli	Don't Get Pumped Up About Pumping It In Medtronic and Eli Lilly team up against Parkinson's.
The Motley Fool March 15, 2011 Brian Orelli	Extending the Competition in Parkinson's Disease Impax's extended-release drug looks good.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
The Motley Fool December 5, 2007 Brian Orelli	Early Bird Gets the MS Worm Teva's multiple sclerosis drug COPAXONE performs well in a label-expanding trial.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
The Motley Fool August 27, 2008 Brian Orelli	Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect.
The Motley Fool March 23, 2009 Brian Orelli	Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
The Motley Fool February 26, 2008 Brian Orelli	The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments.
The Motley Fool January 13, 2011 Brian Orelli	FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool December 15, 2010 Brian Orelli	Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
American Family Physician December 15, 2006 Rao et al.	Parkinson's Disease: Diagnosis and Treatment Family physicians should have a good understanding of Parkinson's disease because of its increasing prevalence as the population ages. Treatment should be individualized to decrease symptoms while minimizing motor and nonmotor complications.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool September 10, 2010 Brian D. Pacampara	A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology.
The Motley Fool July 10, 2009 Brian Orelli	Is the News Good or Bad? Who Cares! Sell! A trial comparing Merck's and Schering-Plough's cholesterol drug Zetia to Abbott Labs' Niaspan was ended early, causing a sell-off of Merck stock.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.
The Motley Fool August 10, 2011 Brian Orelli	A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
Wired August 24, 2009 Steve Silberman	Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology.
The Motley Fool December 15, 2008 Brian Orelli	Medicine Gets a Little More Personal Genetic testing and personalized medicine are still in their infancy, but it's an emerging industry that should be huge in the long run. Which companies stand to benefit from it?
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool March 15, 2010 Brian Orelli	Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all.
The Motley Fool February 25, 2008 Brian Orelli	The Biologic That Keeps on Giving Just a month after Abbott Laboratories receives a fifth approval for its anti-inflammatory Humira, the FDA approved the biotech drug to treat yet another disease.
The Motley Fool November 28, 2008 Brian Orelli	Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug?
The Motley Fool February 20, 2008 Brian Orelli	Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note.
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool August 16, 2006 S.J. Caplan	Abbott Labs' Latest Leaps Generating increased goodwill while potentially expanding its HIV drug market, together with marking progress in its new vascular stent business, proved to be a potent formula for lifting Abbott's shares early this week. Investors, take note.
Managed Care September 2005 Thomas Morrow	Dual-Treatment Approach to Parkinson's Disease The treatment of Parkinson's disease is complicated. Patients may benefit from a dual approach that uses medical therapy with new innovative treatment systems.
The Motley Fool October 24, 2011 Brian Orelli	Biotech Blunder Turned 20% Overnight Gain Exelixis gets good data, even if it wasn't exactly what it was expecting.
The Motley Fool May 14, 2008 Brian Orelli	Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool September 29, 2011 Brian Orelli	Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now.
The Motley Fool April 8, 2005 David Nierengarten	The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool September 11, 2009 Brian Orelli	A Congress Full of Headaches And no drug to fix it. Merck's migraine drugs that block the calcitonin gene-related peptide receptor had such potential to treat what ails me and our government servants. That is, until side effects started popping up.
American Family Physician December 15, 2006	Parkinson's Disease: What You Should Know What is Parkinson's disease?... How can I tell if I have Parkinson's disease?... How will my doctor know if I have it?... How is Parkinson's disease treated?... etc.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.